Prime Medicine (PRME) Common Equity (2021 - 2026)

Prime Medicine's Common Equity history runs 6 years deep, the most recent figure standing at $76.7 million for Q1 2026.

• Quarterly Common Equity fell 28.27% year-over-year to $76.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.7 million (down 28.27% YoY) and the FY2025 annual result came in at $120.9 million, down 21.08% from the prior year.
• Common Equity was $76.7 million for Q1 2026 at Prime Medicine, down from $120.9 million in the prior quarter.
• Across five years, Common Equity topped out at $316.3 million in Q4 2022 and bottomed at -$223.1 million in Q3 2022.
• A 5-year average of $111.0 million and a median of $153.1 million in 2024 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 302.42% in 2022, while the deepest fall reached 136.29% in 2022.
• Prime Medicine's Common Equity stood at $316.3 million in 2022, then plunged by 57.92% to $133.1 million in 2023, then grew by 15.09% to $153.1 million in 2024, then dropped by 21.08% to $120.9 million in 2025, then plunged by 36.54% to $76.7 million in 2026.
• Business Quant data shows PRME's Common Equity at $76.7 million in Q1 2026, $120.9 million in Q4 2025, and $161.8 million in Q3 2025.